Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy
NCT06558084
·
clinicaltrials.gov ↗
COMPLETED
Status
64
Enrollment
OTHER
Sponsor class
Conditions
Toxicity, Drug
Progression, Disease
Interventions
DRUG:
CDK4/6 Inhibitor
Sponsor
Ain Shams University